Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Our healthy balance sheet and cash flow outlook benefit from our efficient service-based model that drives strategic flexibility, strong margins and attractive returns on capital |
| Last quarter, we talked with you about Accredo's extensive clinical expertise in the assets that provide us with a competitive advantage in this fast-growing specialty pharmacy market, which continues to be an important source of growth for our company |
| And our team leads in day in, day out, working to make a positive difference, for those we have the benefit to serve, those we have the benefit to partner with, as well as our orientation around making a positive difference in the communities we work, serve and play in each and every day |
| We had another quarter of strong performance, and we remain on pace for a year of sustained momentum in 2023 |
| With the strength of capabilities across our health services and benefits platforms, we are continuing to deliver on our mission for those we serve as we continue to grow our company |
| Our tailwinds include revenue growth, inclusive of the full launch of our Centene relationship starting January 1, and continued momentum of the biosimilar opportunity to drive more savings to benefit our patients and clients |
| In the third quarter, we delivered $49 billion in total revenue, adjusted earnings per share of $6.77, continued strong cash flow generation across our franchise, all while continuing to reinvest back in our business to fund growth, expansion and ongoing innovation |
| These results are strong, and they show how we're continuing our track record of strong, sustained performance |
| With our Evernorth Health Services and Cigna Healthcare Benefits platform, we are executing well in a dynamic period and fueling customer growth with our deep clinical expertise, innovative solutions and breadth of market-leading capabilities |
| Just to highlight and summarize our dialogue today, we are very pleased with our performance for the quarter and the momentum we've been able to carry now through 3 quarters of the year |
| So in that line item, you can think of 95% plus of the volume is home delivery, and less than 5% is specialty scripts, but attractive growth in specialty, which continues to drive the double-digit revenue growth that we've seen in that business all year |
| We increased our outlook for adjusted EPS to at least $24.75 for full year 2023, as well as increasing the overall outlook we have for revenue, customer lives and cash flow based on our strong performance |
| Our businesses are performing well, and we now expect to deliver adjusted earnings per share of at least $24.75 for full year 2023 |
| Specialty scripts continue to grow at attractive rates, so I think mid- to high single-digit-type unit growth |
| We have scale to mature businesses that drive foundational growth, and businesses in faster-growing market segments that contribute accelerated growth |
| We fuel additional growth through cross enterprise leverage as we bring together the power of our talent, client relationships, differentiated capabilities and innovation from across our company |
| Next, I'll share how we have deliberately shaped our portfolio of businesses that are well positioned for today's market needs |
| We would expect that over time, we'll be well positioned to harness the power of competition to improve the affordability to bring the cost down |
| Evernorth Health Services continues to demonstrate a proven ability to create value with differentiated pharmacy care and benefits capabilities |
| But we're confident we're going to see the margin expansion |
| We are continuing to innovate and provide our clients with expanded choice as well as market-leading value |
| So I think that's it's a huge positive in terms of the margin expectation |
| We also anticipate improvement in our individual exchange margins next year driven by our pricing actions taken in targeted geographies |
| We have a leadership position in addressing a substantial market opportunity with the expanded wave of pharmacological innovation that is reshaping the health care landscape |
| At Evernorth, we are driving better experience, clinical outcome and affordability for patients and clients, given our deep clinical expertise, strong relationships with pharmaceutical manufacturers, as well as with physicians |
| As David just referenced, we're really pleased with the growth in the MA book year-to-date |
| 2023 was a very good year of growth for us in terms of this business portfolio, and our market expansion plans are on track for 2024 |
| Growing at Evernorth's clinical expertise, breadth and depth of data and analytical insights, InCircle Rx guides patients to the most effective care and helps improve affordability for clients |
| We are uniquely well positioned to make medicine more accessible, affordable and clinically coordinated for those we serve as well as to continue to drive growth for our company |
| First, as I noted in my prepared remarks, we're pleased with the Stars position, the stable, strong Stars position we have, and continued traction of our ongoing focus to expand our geographic footprint |
| Statement |
|---|
| For 2024, we expect to continue running below our long-term target margin range in this business |
| But historically, companies that have done that have seen really significant deterioration of enrollment |
| As it relates to the margin profile, as we expected, our 2023 margins continue to be below our long-term target margin range, which is 4% to 5% on this book of business |
| And as we shared in our second quarter call, we anticipate the individual exchange book to run below our target margins in 2023, and our long-term target for this business is 4% to 6% |
| You may recall that we had been anticipating some economic weakness late in 2023, but this has not yet materialized in any notable impact on our customer volumes |
| Lastly, in your comment, we do recognize that the PDP landscape is disrupted, based on some of the legislative and policy activities that have transpired |
| For example, stress, anxiety, [indiscernible], other mental health conditions create challenges for employers who need a healthy, engaged workforce, and we continue to expand the behavioral health solutions we offer through Evernorth Care businesses |
| Given these actions, we are likely to have fewer customers in the individual exchange business relative to where we are in 2023 |
| And within the MA book specifically, throughout the entire year, we've seen elevated utilization in both outpatient and professional services in particular |
| There were some drops in that |
| Many of the treatments that are coming to market are pressuring affordability with high list prices from drug manufacturers |
| Curious if that's what's driving your 200,000 member guidance increase? You're expecting another big slug of those members in the fourth quarter |
| These statements are subject to risks and uncertainties that could cause actual results to differ materially from our current expectations |
| But given the relatively small numbers there, they're outweighed by what happens in home delivery |
| So I'm curious on that |
| we've said from the beginning that the adoption of biosimilars is going to be more extended and slower process |
| A description of these risks and uncertainties is contained in the cautionary note to today's earnings release and in our most recent reports filed with the SEC |
Please consider a small donation if you think this website provides you with relevant information